Immunising the HIV-infected child: A view from sub-Saharan Africa

Vaccine

Volumn 30, Issue SUPPL.3, 2012, Pages

  Mphahlele, M Jeffrey ^a   Mda, Siyazi ^a  

^a SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

Author keywords

BCG; Childhood vaccines; HIV; Immunisation; Immunocompromised; Live attenuated vaccines

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

AFRICA SOUTH OF THE SAHARA; DRUG SAFETY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENCE; INFLUENZA VACCINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AFRICA SOUTH OF THE SAHARA; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 84865642412     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.040     Document Type: Review

References (55)

1. Davis L.G., Weber D.J., Lemon S.M. Horizontal transmission of hepatitis B virus. Lancet 1989, 1(8643):889-893.
2. Dabis F., Ekpini E.R. HIV-1/AIDS and maternal and child health in Africa. Lancet 2002, 359(9323):2097-2104.
3. UNAIDS Report on the Global AIDS Epidemic 2010. [accessed 10.08.11]. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/20101123_globalreport_en.pdf.
4. Moss W.J., Clements C.J., Halsey N.A. Immunisation of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003, 81(1):61-70.
5. Thio C.L. Hepatitis B in human immunodeficiency virus infected patients: epidemiology, natural history, and treatment. Semin Liver Dis 2003, 23(2):125-136.
6. Centres for Disease Control and Prevention Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009, 58(September (RR-11)):1.
7. Burnett R.J., Kramvis A., Dochez C., Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. Vaccine 2012, 30(Suppl. 3):C45-C51.
8. Botha M.H., Dochez C. Introducing human papillomavirus vaccines into clinical practice in South Africa. Vaccine 2012, 30(Suppl. 3):C28-C34.
9. Mahdi S.A., Cohen C., von Gottberg A. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: testimony to success in translating research into policy. Vaccine 2012, 30(Suppl. 3):C21-C27.
10. Simani O.E., Leroux-Roels G., François G., Burnett R.J., Meheus A., Mphahlele M.J. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine 2009, 27(January (1)):146-151.
11. Crane H.M., Dhanireddy S., Kim H.N., Ramers C., Dellit T.H., Kitahata M.M., et al. Optimal timing of routine vaccination in HIV-infected persons. Curr HIV/AIDS Rep 2009 May, 6(2):93-99.
12. Sutcliffe C.G., Moss M.J. Do children infected with HIV receiving HAART need to be revaccinated?. Lancet Infect Dis 2010, 10(September (9)):630-642.
13. World Health Organisation. Weekly Epidemiological Record, 2007; 82 (21): 186-96. http://www.who.int/wer.
14. World Health Organisation. Weekly Epidemiological Record, 2011; 86 (5): 37-44. http://www.who.int/wer.
15. Steele A.D., Cunliffe N., Tumbo J., Madhi S.A., De Vos B., Bouckenooghe A. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. J Infect Dis 2009, 200(November (Suppl. 1)):S57-S62.
16. Steele A.D., Madhi S.A., Louw C.E., Bos P., Tumbo J.M., Werner C.M., et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr Infect Dis J 2011, 30(February (2)):125-130.
17. Hesseling A.C., Cotton M.F., Fordham von Reyn C., Graham S.M., Gie R.P., Hussey G.D. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008, 12(December (12)):1376-1379.
18. Azzopardi P., Bennett C.M., Graham S.M., Duke T. Bacille Calmette-Guérin vaccine-related disease in HIV-infected children: a systematic review. Int J Tuberc Lung Dis 2009, 13(November (11)):1331-1344.
19. Zhang Q., Wang L., Jiang Y., Fang L., Pan P., Gong S., et al. Early infant Human immunodeficiency virus type 1 detection suitable for resource-limited settings with multiple circulating subtypes by use of nested three-monoplex DNA PCR and dried blood spots. J Clin Microbiol 2008, 46(February (2)):721-726.
20. Goga A., Dinh T.-H., Jackson D. Results of an evaluation of effectiveness of the National PMTCT Programme at six weeks postpartum, South Africa. 5th South African AIDS conference 2011.
21. Oshitani H., Suzuki H., Mpabalwani M.E., Mizuta K., Numazaki Y. Measles case fatality by sex, vaccination status, and HIV-1 antibody in Zambian children. Lancet 1996, 348(9024):451.
22. Moss W.J., Fisher C., Scott S., Monze M., Ryon J.J., Quinn T.C., et al. HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. Clin Infect Dis 2008, 46(4):523-527.
23. Sension M.G., Quinn T.C., Markowitz L.E., Linnan M.J., Jones T.S., Francis H.L., et al. Measles in hospitalized African children with human immunodeficiency virus. Am J Dis Child 1988, 142(12):1271-1272.
24. Breña A.E., Cooper E.R., Cabral H.J., Pelton S.I. Antibody response to measles and rubella vaccine by children with HIV infection. J Acquir Defic Syndr 1993, 6(10):1125-1129.
25. Jason J., Murphy J., Sleeper L.A., Donfield S.M., Warrier I., Arkin S., et al. Immune and serologic profiles of HIV-infected and noninfected hemophilic children and adolescents Hemophilia Growth and Development Study Group. Am J Hematol 1994, 46(1):29-35.
26. Moss W.J., Scott S., Mugala N., Ndhlovu Z., Beeler J.A., Audet S.A., et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 2007, 196(3):347-355.
27. Helfand R.T., Witte D., Fowlkes A., Garcia P., Yang C., Fudzulani R., et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis 2008, 198(10):1457-1465.
28. Nair N., Moss W.J., Scott S., Mugala N., Ndhlovu Z.M., Lilo K., et al. HIV-1 infection in Zambian children impairs the development and avidity of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis 2009, 2006(7):1031-1038.
29. Palumbo P., Hoyt L., Demasio K., Oleske J., Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992, 11(12):1008-1014.
30. Arpadi S.M., Markowitz L.E., Baughman A.L., Shah K., Adam H., Wiznia A., et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996, 97(5):653-657.
31. Waibale P., Bowlin S.J., Mortimer E.A, Whalen C. The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda. Int J Epidemiol 1999, 28(2):341-356.
32. Embree J.E., Datta P., Stackiw W., Sekla L., Braddick M., Kreiss J.K., et al. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J Infect Dis 1992, 165(2):262-267.
33. Scott S., Moss W.J., Cousens S., Beeler J.A., Audet S.A., Mugala N., et al. the influence of HIV-1 exposure on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis 2007, 45(11):1417-1424.
34. World Health Organisation. Weekly Epidemiological Record No. 14, 2004: 130-42. http://www.who.int/wer.
35. Moss W.J., Cutts F., Griffin D.E. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis 1999, 29(1):106-112.
36. Scott P., Moss W.J., Gilani Z., Low N. Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. J Infect Dis 2011, 204(Suppl. 1):S164-S178.
37. World Health Organisation. Polio vaccines and polio immunization in the pre-eradication era: Weekly Epidemiological Record, WHO position paper. No. 23, 2010; 85: 213-28.
38. Ion-Nedelcu N., Dobrescu A., Strebel P.M., Sutter R.W. Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet 1994, 343:51-52.
39. Chitsike I., van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report. BMJ 1999, 318:841-843.
40. Sangrujee N., Cáceres V.M., Godni S.L. Cost analysis of post-polio certification immunisation policies. Bull World Health Organ 2004, 82:9-15.
41. Halsey N.A., Pinto J., Espinosa-Rosales F., Faure-Fontenla M.A., da Silva E., Khan A.J., et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ 2004, 82:3-8.
42. Schoub B.D. Will the three steps for containment of poliovirus be enough to convince policy-makers?. Bull World Health Organ 2004, 82:63.
43. Schatzmayr H.G. Poliovirus vaccine strains will continue to circulate long after wild strains have been eradicated. Bull World Health Organ 2004, 82:65.
44. Staples J.E., Gershman M., Fischer M., Centers for Disease Control and Prevention (CDC) Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(July (RR-7)):1-27.
45. Thomas R.E., Lorenzetti D.L., Spragins W., Jackson D., Williamson T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 2012, 86(February (2)):359-372.
46. Klein M.B., Lu Y., DelBalso L., Cote S., Boivin G. Influenza virus infection is a primary cause of febrile respiratory illness in HIV infected adults, despite vaccination. Clin Infect Dis 2007, 45:234-240.
47. Kunisaki K.N., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9(August (8)):493-504.
48. Green R.J., Feldman C., Schoub B., Richards B.A., Madhi S.A., et al. Influenza guideline for South Africa - update 2008. S Afr Med J 2008, 98:223-230.
49. Centres for Disease Control and Prevention General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2006, 55(RR15).
50. World Health Organisation. [accessed 10.08.11]. http://www.who.int/csr/disease/swineflu/en/index.html.
51. Glesby M.J., Hoover D.R., Farzadegan H., Margolick J.B., Saah A.J. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996, 174(6):1332-1336.
52. Atashili J., Kalilani L., Adimora A.A. Efficacy and clinical effectiveness in reducing the incidence of influenza in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006, September:38.
53. Levin M.J., Song L.Y., Fenton T., Nachman S., Patterson J., Walker R., et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008, 26(August (33)):4210-4217.
54. Giannatassio A., Lo Vecchio A., Albano F., Giacomet V., Barbarino A., Guarino A. Flu and pneumococcal immunisations in HIV-infected: methodological quality of current recommendations. BMJ Qual Saf 2011, 20(May (5)):432-439.
55. Skiest D.J., Machala T. Comparison of the effects of acute influenza infection and influenza vaccination on HIV viral load and CD4 cell counts. J Clin Virol 2003, 26(April (3)):307-315.